Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy

Arauz-Pacheco, Carlos; Ramirez, Luis C.; Ríos, Juan Manuel; Raskin, Philip

doi:10.1016/0002-9343(90)90227-5

Cited by 50 publications

(25 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the interaction of the antidiabetic and the antihypertensive drug may be brought out. There are a few interactions between glipizide and other drugs (Connacher et al, 1987;Arauz-Pacheco et al, 1990;Kivisto and Neuvonen, 1991;Kradjan et al, 1994;Niemi et al, 2001). However, pharmacokinetic interaction between glipizide and carvedilol has not been reported in vivo.…”

Section: Discussionmentioning

confidence: 99%

Effects of Glipizide on the Pharmacokinetics of Carvedilol after Oral and Intravenous Administration in Rats

Lee¹,

Choi

2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

Abstractscavenges free radicals of oxygen (Feuerstein et al., 1997). It is used to treat systemic arterial hypertension (Cournot et al., 1992;Lund-Johansen et al., 1992) and congestive heart failure (DasGupta et al., 1991) and is purported to improve exercise capacity (Cleland et al., 1996;Hampton, 1996) and longevity in humans .Carvedilol is well absorbed from the gastrointestinal tract, but is subject to considerable fi rst-pass metabolism in the intestinal and/or liver (McTavish et al., 1993;Morgan, 1994). Carvedilol is more than 98% bound to plasma proteins. Carvedilol is metabolized by both oxidation and conjugation pathways in the liver into some metabolites (Neugebauer et al., 1987;Neugebauer and Neubert, 1991). The oxidation pathways are mainly catalyzed by CYP2C9 enzymes in human (McTavish et al., 1993;Morgan, 1994;Oldham and Clarke, 1997), and then CYP2D6 is responsible for the formation of 4'-hydroxy carvedilol and 5'-hydroxy carvedilol, and both metabolites are excreted into urine (Neugebauer and Neubert, 1991). Since carvedilol is a substrate of both CYP2C9 en-

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Glipizide on the Pharmacokinetics of Carvedilol after Oral and Intravenous Administration in Rats

Lee¹,

Choi

2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Captopril can lower blood glucose by increasing insulin sensitivity, so the antidiabetic effect is increased and leads to greater hypoglycemic effects [14].…”

Section: Captopril With Glibenclamidementioning

confidence: 99%

Analysis of Potential Drugs Interaction on Antihypertension Drugs Prescription in Community Health Center of Sukmajaya District in Period of June-November 2015

Puspitasari

Azizahwati

Hidayat

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: Hypertension is a common disease around the world. Depending on the severity or the presence of other diseases, whether related or unrelated, additional drug therapy may be required to optimize treatment and to reduce the side effects of drugs. The use of drugs in large amounts may increase the risk of drug interactions. The purpose of this research was to evaluate the characteristics of hypertension patients, prescriptions, and potential drug interactions in hypertensive patients in the Sukmajaya Community Health Center from June to November 2015.Methods: This research used a descriptive analytic method and the data were retrospectively obtained. Results:The results were based on the analysis of 350 prescriptions of female (67.43%) and male (32.57%) patients, with the highest prevalence of hypertension occurring at the age of ≥55 years. Potential drug interactions were analyzed using Micromedex. The most frequent potential interaction resulted from the combined use of captopril and non-steroidal anti-inflammatory drugs. The most frequent mechanism of drug interaction was pharmacokinetics (51.06%). The chi-square test results showed a significant relationship between the number of prescribed drugs and potential interactions at a probability value of 0.0001 and an odds ratio of 5.940 (15.588-2.263). Conclusions:With respect to interaction mechanism, pharmacokinetic (51.06%) was the most frequent and 61.70% of potential cases involved a moderate interaction risk.

show abstract

“…Interestingly, the highest risk of severe hypoglycemias among all patients on oral antidiabetic agents observed was in those patients concomitantly treated with ACE inhibitors and oral hypoglycemic agents [1]. Apart from systematic studies, a number of case reports seem to confirm an increased risk of hypoglycemias in patients with diabetes treated with ACE inhibitors [5][6][7][8]. For example, Arauz-Pacheco and colleagues reported two patients with a stable noninsulin dependent diabetes treated with sulfonylurea in whom hypoglycemic episodes occurred almost immediately after the initiation of ACE-inhibitor therapy for hypertension [5].…”

Section: Introductionmentioning

confidence: 99%

“…Apart from systematic studies, a number of case reports seem to confirm an increased risk of hypoglycemias in patients with diabetes treated with ACE inhibitors [5][6][7][8]. For example, Arauz-Pacheco and colleagues reported two patients with a stable noninsulin dependent diabetes treated with sulfonylurea in whom hypoglycemic episodes occurred almost immediately after the initiation of ACE-inhibitor therapy for hypertension [5]. Conversely, no episodes had occurred in these patients earlier, when on glibenclamide monotherapy.…”

Section: Introductionmentioning

confidence: 99%

Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study

Rave

Flesch

Kühn‐Velten³

et al. 2005

Diabetes Metab. Res. Rev.

View full text Add to dashboard Cite

show abstract

Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy

Cited by 50 publications

References 18 publications

Effects of Glipizide on the Pharmacokinetics of Carvedilol after Oral and Intravenous Administration in Rats

Effects of Glipizide on the Pharmacokinetics of Carvedilol after Oral and Intravenous Administration in Rats

Analysis of Potential Drugs Interaction on Antihypertension Drugs Prescription in Community Health Center of Sukmajaya District in Period of June-November 2015

Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study

Contact Info

Product

Resources

About